GRASPA

DRUG6 trials

Sponsors

ERYtech Pharma, Birgitte Klug Albertsen

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseAcute Myeloid LeukemiaPancreatic Cancer

Phase 1

Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia

CompletedNCT00723346

ERYtech PharmaAcute Lymphoblastic Leukemia

Start: 2006-01-31End: 2009-03-31Updated: 2012-01-11

Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer

CompletedNCT01523808

ERYtech PharmaPancreatic Cancer

Start: 2009-11-30End: 2011-03-31Updated: 2021-10-15

Phase 2

GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia

CompletedNCT01518517

ERYtech PharmaAcute Lymphoblastic Leukemia, in Relapse

Start: 2009-12-31End: 2016-10-31Updated: 2022-02-02

Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia

CompletedNCT01523782

ERYtech PharmaAcute Lymphoblastic Leukemia

Start: 2009-04-30End: 2012-10-31Updated: 2021-10-15

GRASPA Treatment for Patients With Acute Myeloblastic Leukemia

CompletedNCT01810705

ERYtech PharmaAcute Myeloid Leukemia

Start: 2013-02-28End: 2017-11-10Updated: 2022-02-21

Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase

CompletedNCT03267030

Birgitte Klug AlbertsenAcute Lymphoblastic Leukemia

Start: 2017-08-23End: 2020-10-22Updated: 2024-03-15

Related Papers

Asparaginase encapsulated in erythrocytes as second‐line treatment in hypersensitive patients with acute lymphoblastic leukaemia

British Journal of Haematology2022-03-2822 citations

NOR-GRASPALL2016 (NCT03267030): Asparaginase Encapsulated in Erythrocytes (eryaspase) - a Promising Alternative to Peg-Asparaginase in Case of Hypersensitivity

Blood2020-11-056 citations

Pharmacodynamic characterization of eryaspase (L-asparaginase encapsulated in red blood cells) in combination with chemotherapy in a phase 2/3 trial in patients with relapsed acute lymphoblastic leukemia (NCT01518517).

Journal of Clinical Oncology2018-05-202 citations

A <scp>P</scp>hase 2 study of <scp>L</scp>‐asparaginase encapsulated in erythrocytes in elderly patients with <scp>P</scp>hiladelphia chromosome negative acute lymphoblastic leukemia: The <scp>GRASPALL/GRAALL‐SA</scp>2‐2008 study

American Journal of Hematology2015-06-2076 citations

Drug monitoring of ERY001 (erythrocyte encapsulated L-asparaginase) and native L-asparaginase (L-ASP) in combination with COOPRALL regimen in Phase 3 randomized trial in patients with relapsed acute lymphoblastic leukemia.

Journal of Clinical Oncology2015-05-205 citations

GRASPA-AML 2012-01 study (NCT01810705): A multicenter, open, randomized phase 2b trial evaluating ERY001 (L-asparaginase encapsulated in red blood cells) plus low-dose cytarabine vs low-dose cytarabine alone, in treatment of newly diagnosed acute myeloid leukemia (AML) elderly patients, unfit for intensive chemotherapy.

Journal of Clinical Oncology2015-05-204 citations

L-Asparaginase Sensitivity and Asparagine Synthetase Expression In Primary Tumor Cells From AML Patients

Blood2013-11-152 citations